Spectris plc: Director/PDMR Shareholding
This notification made under Article 19 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").
On 18 March 2025, Spectris plc (the "Company") was notified that on the same day,
Andrew Heath, Chief Executive, and Derek Harding, President, Spectris Scientific acquired 18,730 and 12,104 ordinary shares of 5p each ("Ordinary Shares") in the Company respectively following the exercise of options granted under the terms of the Spectris Deferred Bonus Plan ("DBP") on 17 March 2022.
Of the 18,730 Ordinary Shares acquired by Mr Heath, 8,848 were sold to fund the option cost and the income tax / national insurance liability at a sale price of £25.3180 and the remaining 9,882 Ordinary Shares were retained and immediately transferred into a nominee account on his behalf.
Of the 12,104 Ordinary Shares acquired by Mr Harding, 5,719 were sold to fund the option cost and the income tax / national insurance liability at a sale price of £25.3180 and the remaining 6,385 Ordinary Shares were retained and immediately transferred into a nominee account on his behalf.
The forms for this transaction, as required under MAR, follows:
| 1 | Details of the persons discharging managerial responsibilities | |
| a) | Name(s) | Andrew Heath, Chief Executive |
| 2 | Reason for the notification | |
| a) | Position/status | Director/PDMR |
| b) | Initial notification/Amendment | Initial Notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Spectris plc |
| b) | LEI | 213800Z4CO2CZO3M3T10 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 5p each
|
| b) | Nature of the transaction | (i) Exercise of options over 18,730 Ordinary Shares under the terms of the DBP granted on 17 March 2022. (ii) Subsequent sale of 8,848 Ordinary Shares to cover option cost and income tax / national Insurance liabilities arising on exercise. (iii) Transfer of remining 9,882 Ordinary Shares into a nominee account on Mr Heath's behalf.
| ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| (i) Acquisition
£0.05
£0.00
|
17,407 (Share Award granted as a nominal cost option under the terms of the DBP) 1,323 (Dividend equivalent shares awarded in lieu of dividend accrual on nominal cost option)
| |||
| | | (ii) Sale
£25.3180 |
8,848 | |
| | | (iii) Transfer
£nil |
9,882 | |
| d) | Aggregated information | (i) Acquisition
| ||
| Price per share | £0.0465 | |||
| Volume | 18,730 | |||
| | | Price | £870.35 | |
| | | (ii) Sale | ||
| | | Price per share | £25.3180 | |
| | | Volume | 8,848 | |
| | | Price | £224,014.07 | |
| | | (iii) Transfer
| ||
| | | Price per share | £0.0000 | |
| | | Volume | 9,882 | |
| | | Price | £0.00 | |
| e) | Date of the transaction | 18 March 2025
| ||
| f) | Place of the transaction | Outside of a trading venue
| ||
| 1 | Details of the persons discharging managerial responsibilities | ||
| a) | Name(s) | Derek Harding, President Spectris Scientific | |
| 2 | Reason for the notification | ||
| a) | Position/status | Director/PDMR | |
| b) | Initial notification/Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Spectris plc | |
| b) | LEI | 213800Z4CO2CZO3M3T10 | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 5p each
| |
| b) | Nature of the transaction | (i) Exercise of options over 12,104 Ordinary Shares under the terms of the DBP granted on 17 March 2022. (ii) Subsequent sale of 5,719 Ordinary Shares to cover option cost and income tax / national Insurance liabilities arising on exercise. (iii) Transfer of remaining 6,385 Ordinary Shares into a nominee account on Mr Harding's behalf.
| |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| (i) Acquisition
£0.05
£0.00
|
11,249 (Share Award granted as a nominal cost option under the terms of the DBP) 855 (Dividend equivalent shares awarded in lieu of dividend accrual on nominal cost option)
| ||
| | | (ii) Sale
£25.3180 |
5,719 |
| | | (iii) Transfer
£nil |
6,385 |
| d) | Aggregated information | (iv) Acquisition
| |
| Price per share | £0.0465 | ||
| Volume | 12,104 | ||
| | | Price | £562.45 |
| | | (v) Sale | |
| | | Price per share | £25.3180 |
| | | Volume | 5,719 |
| | | Price | £144,793.91 |
| | | (vi) Transfer
| |
| | | Price per share | £0.0000 |
| | | Volume | 6,385 |
| | | Price | £0.00 |
| e) | Date of the transaction | 18 March 2025
| |
| f) | Place of the transaction | Outside of a trading venue
| |
Name of contact and telephone number for queries:
Stephanie Dyer
Group Reward Executive
07386 686 720
For and on behalf of Spectris plc
LEI Number: 213800Z4CO2CZO3M3T10
Date: 19 March 2025
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
